All
For Best Survival in Ovarian Cancer, Chemotherapy Doses Must be in Line with Body Weight
July 15th 2015According to professional practice guidelines, women with ovarian cancer should get doses of chemotherapy that are based on their weight. When they receive less than that, a new study has found, the result can be poorer survival.
One Million and Counting ... in Support of Bladder Cancer Research
July 15th 2015When my late husband John and I started the Bladder Cancer Advocacy Network (BCAN) in 2005, our goal was not only to raise awareness about bladder cancer, but to change the landscape for this disease by funding research to discover new treatments that will save lives.
Iressa Wins Approval as First-Line Treatment for Certain Non-Small Cell Lung Cancers
July 14th 2015The U.S. Food and Drug Administration has approved Iressa (gefitinib) for the frontline treatment of patients with metastatic non-small cell lung cancer that is positive for EGFR and has one of two additional mutations.
IV Emend Helps Prevent CINV With Moderately Emetogenic Chemotherapy
July 2nd 2015A single intravenous dose of EMEND for Injection was shown to be superior to placebo when either were combined with other anti-vomiting agents for protection against CINV in patients receiving moderately emetogenic chemotherapy.